Introduction
Anesthesia is a drug that causes a reversible loss of sensation. There are several types of anesthetic drugs available in the market, such as general anesthesia, spinal anesthesia, IV regional anesthesia, local anesthesia, peripheral nerve block, and saddle block or caudal anesthesia.
The rising prevalence of cancer, rapid growth in geriatric population, and increasing number of emergency surgeries are some of the major factors driving the growth of the US general anesthesia drugs.
The COVID-19 pandemic has severely impacted healthcare industry. The general anesthesia drugs sector is witnessing challenges in the manufacturing and supply chain, such as delivering products to end users on time and attending to an uneven demand for products.
Table of Contents
Executive Summary
Scope of the report
Research Methodology
Executive Summary
Introduction
5.1 Parent Market/ TAM
5.2 Market Outline
5.3 Market Segmentation
6. Five Force analysis
7. Market Sizing
8. Market segmentation
9. Geographical Landscape
9.1 U.S
10. Growth drivers
10.1 The rising global geriatric population
10.2 Rising number of emergency surgeries
11. Key Market Trends
12. Impact of Covid-19
13. Challenges
14. Customer Insights analysis
15. Major Market Players
15.1 Baxter International,,,,,
15.2 Hikma Pharmaceuticals
15.3 Pfizer
15.4 Piramal Enterprises Limited
15.5 AbbVie
15.6 Fresenius
15.7 Par Pharmaceutical
15.8 Gilead Sciences
15.9 Bayer
15.10 Novartis
16. Recent Developments
17. Future Scope
18. Strategic Recommendations
Market Overview
U.S general anesthesia market is expected to have incremental growth of $2.50 billion during 2020-2025.
Growth momentum is expected to accelerate during the forecast period with 4.36% CAGR.
The intravenous drugs segment is expected to account for the largest market share in 2020.
Growth in this market segment can largely be attributed to the massive patient footfall in hospitals and the increasing number of surgeries performed in these facilities.
Key Trends
With the increase in the number of surgeries and the increasing geriatric population in the region, the demand for propofol drugs is expected to create potential demand in the near future.
The patent expiration of Lusedra is expected to pave the way for generic drugs to enter the US market, which is expected to offer a significant growth outlook for the key players.
Key Market Players
Some of the key players in the market are Baxter International, Hikma Pharmaceuticals, Pfizer, Piramal Enterprises Limited, AbbVie, Fresenius.
Prominent companies are adopting various business strategies, such as partnerships, mergers & acquisitions, and Research & Development to strengthen their market presence.
Growth Drivers and Challenges
The rising global geriatric population is one of the crucial driving factors.
Evolving industrialization in growing economies is resulting in the prevalence and early onset of chronic diseases. This is indirectly increasing the demand for general anesthesia during treatment.
The rising number of emergency surgeries is also driving the market.